Journal article
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy
Anti-cancer drugs, Vol.18(7), pp.817-820
08/2007
DOI: 10.1097/CAD.0b013e3280a02f17
PMID: 17581304
Abstract
The aim of this study was to evaluate the activity and toxicity of capecitabine as third-line treatment in patients with advanced renal cell carcinoma for whom immunotherapy had failed. Twenty-one patients with metastatic clear renal cell carcinoma were enrolled. Capecitabine was administered orally twice daily at a dosage of 2500 mg/m(2) for 14 days, followed by 7 days of rest. The median number of administered cycles was five (1-13). One patient (4.8%) achieved a remission after eight treatment cycles. Stable disease was observed in nine patients (42.8%), whereas 11 progressed (52.4%). The estimated median time to progression was 3.6 months (confidence interval: 1.4 to 5.2). The estimated median overall survival was 7.2 months (confidence interval: 4.6 to 8.8). The regimen was well tolerated and no unexpected toxic effects were observed. Capecitabine as third-line treatment showed a favourable toxicity profile, but exhibited low activity in patients with advanced renal cell carcinoma after failing immunotherapy.
Details
- Title: Subtitle
- Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy
- Creators
- Roberto Petrioli - University of SienaLoretta Paolelli - University of SienaEdoardo Francini - University of SienaStefania Marsili - University of SienaAlessandra Pascucci - University of SienaAngela Sciandivasci - European Institute of OncologyGiovanni De Rubertis - University of SienaGabriele Barbanti - University of SienaAntonio Manganelli - University of SienaFrancesco Salvestrini - University of SienaGuido Francini - University of Siena
- Resource Type
- Journal article
- Publication Details
- Anti-cancer drugs, Vol.18(7), pp.817-820
- DOI
- 10.1097/CAD.0b013e3280a02f17
- PMID
- 17581304
- NLM abbreviation
- Anticancer Drugs
- ISSN
- 0959-4973
- Number of pages
- 4
- Language
- English
- Date published
- 08/2007
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221245802771
Metrics
1 Record Views